APA (7th ed.) Citation

Keystone, E., Fleischmann, R., Han, C., Smolen, J., Emery, P., Genovese, M., . . . Hsia, E. (2011). PMS57 ASSOCIATION OF CLINICAL REMISSION AND NORMALIZED PATIENT REPORTED OUTCOMES: A VALIDATION OF TREAT-TO-TARGET FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS USING POOLED DATA FROM 3 PHASE III GOLIMUMAB CLINICAL TRIALS. Value in Health, A133. https://doi.org/10.1016/j.jval.2011.02.741

Chicago Style (17th ed.) Citation

Keystone, E., R. Fleischmann, C. Han, J.S Smolen, P. Emery, M. Genovese, T. Gathany, M. Doyle, and E. Hsia. "PMS57 ASSOCIATION OF CLINICAL REMISSION AND NORMALIZED PATIENT REPORTED OUTCOMES: A VALIDATION OF TREAT-TO-TARGET FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS USING POOLED DATA FROM 3 PHASE III GOLIMUMAB CLINICAL TRIALS." Value in Health 2011: A133. https://doi.org/10.1016/j.jval.2011.02.741.

MLA (9th ed.) Citation

Keystone, E., et al. "PMS57 ASSOCIATION OF CLINICAL REMISSION AND NORMALIZED PATIENT REPORTED OUTCOMES: A VALIDATION OF TREAT-TO-TARGET FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS USING POOLED DATA FROM 3 PHASE III GOLIMUMAB CLINICAL TRIALS." Value in Health, 2011, p. A133, https://doi.org/10.1016/j.jval.2011.02.741.